Industry
Biotechnology
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Avi Kapoor
July 15, 2024 | 1:47 pm
Portfolio Pulse from Benzinga Newsdesk
July 15, 2024 | 10:07 am
Portfolio Pulse from Benzinga Newsdesk
June 13, 2024 | 9:15 am
Portfolio Pulse from Benzinga Newsdesk
June 06, 2024 | 10:41 am
Portfolio Pulse from Avi Kapoor
April 22, 2024 | 2:10 pm
Portfolio Pulse from Benzinga Newsdesk
April 22, 2024 | 11:32 am
Portfolio Pulse from Benzinga Newsdesk
April 16, 2024 | 11:37 am
Portfolio Pulse from Benzinga Newsdesk
April 16, 2024 | 11:31 am
Portfolio Pulse from Benzinga Insights
March 12, 2024 | 5:00 pm
Portfolio Pulse from Benzinga Newsdesk
March 12, 2024 | 3:29 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.